Recommended Reading

Eiger BioPharmaceuticals has announced positive results from the Phase 2 PREVENT study of Avexitide in patients with severe Post-Bariatric Hypoglycaemia (PBH), the outcomes were published in Journal of Clinical Endocrinology & Metabolism (Craig, C.M.

W L Gore & Associates (Gore) has launched the GORE Synecor Intraperitoneal Biomaterial in Europe, the Middle East and South Africa.